A5061636827- Histone Deacetylase Inhibitors Research
- Neuroendocrine Tumor Research Advances
- Epigenetics and DNA Methylation
- Lung Cancer Research Studies
- Protein Degradation and Inhibitors
- Pancreatic and Hepatic Oncology Research
- Cell death mechanisms and regulation
- CRISPR and Genetic Engineering
- Cancer Research and Treatments
- Autophagy in Disease and Therapy
- interferon and immune responses
- Cancer Mechanisms and Therapy
- Neuroscience and Neuropharmacology Research
- 14-3-3 protein interactions
- Phagocytosis and Immune Regulation
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- RNA modifications and cancer
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal Tumor Research and Treatment
- Cardiac Ischemia and Reperfusion
- Glioma Diagnosis and Treatment
- NF-κB Signaling Pathways
- Cancer-related molecular mechanisms research
- Medicinal Plants and Neuroprotection
Koç University
2015-2024
German Cancer Research Center
2021-2022
Heidelberg University
2022
University Medical Center Freiburg
2022
University of Freiburg
2021-2022
Bilkent University
2017
Background: Prognostic biomarkers for cancer have the power to change course of disease if they add value beyond known prognostic factors, can help shape treatment protocols, and are reliable.The aim this study was identify such colon understand molecular mechanisms leading stratifications based on these biomarkers.Methods Findings: We used an in house R script (SSAT) silico discovery stage-independent using two cohorts, GSE17536 GSE17537, that include 177 55 patients, respectively.This...
Abstract Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively kill tumor cells. TRAIL resistance in cancers is associated with aberrant expression of the key components apoptotic program. However, how these are regulated at epigenetic level not understood. In this study, we investigated novel mechanisms regulating response glioblastoma multiforme (GBM) cells by a short-hairpin RNA loss-of-function screen. We interrogated 48 genes DNA and histone modification...
Abstract Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor. Despite recent developments in surgery, chemo- radio-therapy, a currently poor prognosis of GBM patients highlights an urgent need for novel treatment strategies. TRAIL (TNF Related Apoptosis Inducing Ligand) potent anti-cancer agent that can induce apoptosis selectively cancer cells. cells frequently develop resistance to which renders clinical application therapeutics inefficient. In this study,...
Abstract Background Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellent therapeutic intervention points various types cancers. Method In this study, we investigated regulators glioblastoma cell survival through CRISPR/Cas9 based genetic ablation screens using a customized sgRNA library EpiDoKOL, which...
Abstract Background Loss-of-function mutations of the multiple endocrine neoplasia type 1 ( MEN1 ) gene are causal to tumor syndrome, but they also commonly found in sporadic pancreatic neuroendocrine tumors and other types cancers. The product, menin, is involved transcriptional chromatin regulation, most prominently as an integral component KMT2A/MLL1 KMT2B/MLL2 containing COMPASS-like histone H3K4 methyltransferase complexes. In a mutually exclusive fashion, menin interacts with JunD...
Glioblastoma Multiforme (GBM) is the most common and aggressive brain tumor, which lacks efficient therapy. TRAIL an antitumor agent that triggers apoptosis selectively on tumor cells, thus can be utilized as therapeutic approach for GBM. However, GBM cells confer resistance how this regulated at a molecular level not completely clear. Epigenetic deregulation has been increasingly recognized hallmark of cancer. In study, we conducted drug screen against selected chromatin modifiers in U87MG...
Abstract Glioblastoma Multiforme (GBM) is the most common and aggressive brain tumor, which lacks efficient therapy. TRAIL an antitumor agent that triggers apoptosis selectively on tumor cells, thus can be utilized as therapeutic approach for GBM. However, GBM cells confer resistance how this regulated at a molecular level not completely clear. Epigenetic deregulation has been increasingly recognized hallmark of cancer. In study, we conducted drug screen against selected chromatin modifiers...
Introduction Glioblastoma multiforme (GBM) is the most common of all malignant brain tumours. Unfortunately, only 5.1% patients survive five years post diagnosis. Therapy options for GBM are very limited, majority receive radiation therapy and chemotherapeutic Temozolomide (TMZ). However, tumours recur making resistance an extremely important issue. Cancers show aberrant global epigenetic alterations, yet, mechanisms that cause not well-known. In this project, role chromatin modifying...
ABSTRACT Glioblastoma is the most common and aggressive primary brain tumor with poor prognosis, highlighting an urgent need for novel treatment strategies. In this study, we investigated epigenetic regulators of glioblastoma cell survival through CRISPR/Cas9 based genetic ablation screens using a customized sgRNA library EpiDoKOL, which targets critical functional domains chromatin modifiers. Screens conducted in multiple lines revealed ASH2L , histone lysine methyltransferase complex...
Loss-of-function mutations of the multiple endocrine neoplasia type 1 (MEN1) gene are causal to MEN1 tumor syndrome, but they also commonly found in sporadic pancreatic neuroendocrine tumors and other types cancers. The product, menin, is involved transcriptional chromatin regulation, most prominently as an integral component KMT2A/MLL1 KMT2B/MLL2 containing COMPASS-like histone H3K4 methyltransferase complexes. In a mutually exclusive fashion, menin interacts with JunD subunit AP-1 ATF/CREB...
Abstract Loss-of-function mutations of the multiple endocrine neoplasia type 1 (MEN1) gene are causal to MEN1 tumor syndrome, but they also commonly found in sporadic pancreatic neuroendocrine tumors and other types cancers. The product, menin, is involved transcriptional chromatin regulation, most prominently as an integral component KMT2A/MLL1 KMT2B/MLL2 containing COMPASS-like histone H3K4 methyltransferase complexes. In a mutually exclusive fashion, menin interacts with JunD subunit AP-1...